Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

665 ARTÍCULOS , VIENDO DEL 181 AL 195

Advances of computer-aided drug design (CADD) in the development of anti-Azheimer's-disease drugs

Niu Y, Lin P.

Drug Discov Today. 2023 Aug;28(8):103665. doi: 10.1016/j.drudis.2023.103665. Epub 2023 Jun 9.

BACE-1 Inhibitors Targeting Alzheimer's Disease

Monteiro KLC, Dos Santos Alcântara MG, Freire NML, Brandão EM, do Nascimento VL, Dos Santos Viana LM, de Aquino TM, da Silva-Júnior EF.

Curr Alzheimer Res. 2023;20(3):131-148. doi: 10.2174/1567205020666230612155953.

Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs

Goodarzi G, Tehrani SS, Fana SE, Moradi-Sardareh H, Panahi G, Maniati M, Meshkani R.

Metab Brain Dis. 2023 Aug;38(6):1769-1800. doi: 10.1007/s11011-023-01225-3. Epub 2023 Jun 19.

siRNA drug delivery across the blood-brain barrier in Alzheimer's disease

Imran Sajid M, Sultan Sheikh F, Anis F, Nasim N, Sumbria RK, Nauli SM, Kumar Tiwari R.

Adv Drug Deliv Rev. 2023 Aug;199:114968. doi: 10.1016/j.addr.2023.114968. Epub 2023 Jun 21.

Pushing the boundaries of brain organoids to study Alzheimer's disease

Cerneckis J, Bu G, Shi Y.

Trends Mol Med. 2023 Aug;29(8):659-672. doi: 10.1016/j.molmed.2023.05.007. Epub 2023 Jun 21.

Editorial: What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?

Middleton LT, Touchon J, Vellas B.

J Prev Alzheimers Dis. 2023;10(3):331-332. doi: 10.14283/jpad.2023.69.

Editorial: Clinical Implementation of Lecanemab: Challenges, Questions and Solutions

Iwatsubo T.

J Prev Alzheimers Dis. 2023;10(3):353-355. doi: 10.14283/jpad.2023.41.

Editorial: Lecanemab: Appropriate Use Recommendations - A Commentary from a European Perspective

Frölich L, Jessen F.

J Prev Alzheimers Dis. 2023;10(3):357-358. doi: 10.14283/jpad.2023.44.

Alzheimer's Disease Treatment: The Search for a Breakthrough

Reiss AB, Muhieddine D, Jacob B, Mesbah M, Pinkhasov A, Gomolin IH, Stecker MM, Wisniewski T, De Leon J.

Medicina (Kaunas). 2023 Jun 4;59(6):1084. doi: 10.3390/medicina59061084.

Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future

Zhang Y, Chen H, Li R, Sterling K, Song W.

Signal Transduct Target Ther. 2023 Jun 30;8(1):248. doi: 10.1038/s41392-023-01484-7.

As a Potential Therapeutic Target, C1q Induces Synapse Loss Via Inflammasome-activating Apoptotic and Mitochondria Impairment Mechanisms in Alzheimer's Disease

Guan PP, Ge TQ, Wang P.

J Neuroimmune Pharmacol. 2023 Sep;18(3):267-284. doi: 10.1007/s11481-023-10076-9. Epub 2023 Jun 29.

Gauging innovation and health impact from biomedical research: survey results and interviews with recipients of EU-funding in the fields of Alzheimer's disease, breast cancer and prostate cancer

Pistollato F, Campia I, Daskalopoulos EP, Bernasconi C, Desaintes C, Di Virgilio S, Kyriakopoulou C, Whelan M, Deceuninck P.

Health Res Policy Syst. 2023 Jun 29;21(1):66. doi: 10.1186/s12961-023-00981-z.

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

Yu HJ, Dickson SP, Wang PN, Chiu MJ, Huang CC, Chang CC, Liu H, Hendrix SB, Dodart JC, Verma A, Wang CY, Cummings J.

EBioMedicine. 2023 Aug;94:104665. doi: 10.1016/j.ebiom.2023.104665. Epub 2023 Jun 29.

Fatigue in Alzheimer's disease: biological basis and clinical management-a narrative review

Angioni D, Raffin J, Ousset PJ, Delrieu J, de Souto Barreto P.

Aging Clin Exp Res. 2023 Oct;35(10):1981-1989. doi: 10.1007/s40520-023-02482-z. Epub 2023 Jul 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias